Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9124739 | 0.80 | ACHE (0.48) | SLC6A4PPARGKMT2AACHE | |
| SCHEMBL23067916 | 0.79 | HPGD (0.49) | HPGDSLC6A4PPARGPPARANFE2L2 | |
| SCHEMBL8909089 | 0.77 | ALDH1A1 (0.43) | SLC6A4PPARGPPARANFE2L2 | |
| SCHEMBL8909407 | 0.77 | CA4 (0.39) | SLC6A4 | |
| SCHEMBL366155 | 0.77 | CA4 (0.39) | SLC6A4 | |
| SCHEMBL9325097 | 0.75 | SLC6A4 (0.49) | HPGDSLC6A4PPARGPPARAMEN1 | |
| SCHEMBL104732 | 0.75 | HPGD (0.51) | HPGDSLC6A4PPARGPPARANFE2L2 | |
| SCHEMBL96595 | 0.73 | HPGD (0.54) | HPGDSLC6A4PPARGPPARANFE2L2 | |
| SCHEMBL16294967 | 0.72 | PPARG (0.53) | HPGDSLC6A4PPARGPPARANFE2L2 | |
| SCHEMBL1619629 | 0.72 | HPGD (0.49) | HPGDSLC6A4PPARGPPARANFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270693-A1 | Ether derivative | UROD, IL5, IL17A | HPGD 82/4885SLC6A4 3793/4885PPARG 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.